289 related articles for article (PubMed ID: 26436722)
41. Efficacy of sequential use of telbivudine in hepatitis B e antigen-positive chronic hepatitis B patients with partial responses to pegylated interferon: a pilot study.
Huang Z; Zhao Z; Zheng Y; Peng L; Lin C; Deng H; Gao Z
J Viral Hepat; 2013 Apr; 20 Suppl 1():52-7. PubMed ID: 23458525
[TBL] [Abstract][Full Text] [Related]
42. Improved efficacy by individualized combination therapy with Peg IFN-a 2a and ADV in HBeAg positive chronic hepatitis B patients.
Wang YD; Zhao CY; Wang W; Shen C; Lu HZ; Zhang L; Yu WY; Zhou JY; Yan WZ
Hepatogastroenterology; 2012 May; 59(115):680-6. PubMed ID: 22441104
[TBL] [Abstract][Full Text] [Related]
43. HBeAg-negative chronic hepatitis B: why do I treat my patients with pegylated interferon-alfa?
Vlachogiannakos J; Papatheodoridis GV
Liver Int; 2014 Feb; 34 Suppl 1():127-32. PubMed ID: 24373089
[TBL] [Abstract][Full Text] [Related]
44. Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D.
Erhardt A; Blondin D; Hauck K; Sagir A; Kohnle T; Heintges T; Häussinger D
Gut; 2005 Jul; 54(7):1009-13. PubMed ID: 15951551
[TBL] [Abstract][Full Text] [Related]
45. Pegylated interferon results in higher serological, but not virological, response rates when compared to continuous entecavir.
Sonneveld MJ; Zoutendijk R; Hansen BE; Janssen HL
Antivir Ther; 2012; 17(8):1605-8. PubMed ID: 22898565
[TBL] [Abstract][Full Text] [Related]
46. Insufficient immunity led to virologic breakthrough in NAs-treated chronic hepatitis B patients switching to Peg-IFN-ɑ.
Huang D; Yan W; Han M; Yuan W; Wang P; Chen Y; Wan X; Luo X; Wu D; Ning Q
Antiviral Res; 2022 Jan; 197():105220. PubMed ID: 34848218
[TBL] [Abstract][Full Text] [Related]
47. [Liver histopathological features influencing HBeAg seroconversion in patients with HBeAg-positive chronic hepatitis B responding to Peg-IFN treatment].
Yan HD; Jiang FR; Zhu CL; Gao GS; Weng PJ; Hu AR; Xu CF; Hu YR; Sheng JF
Zhonghua Gan Zang Bing Za Zhi; 2013 May; 21(5):340-4. PubMed ID: 24025133
[TBL] [Abstract][Full Text] [Related]
48.
Xie DY; Wang SM; Yang JM; Wang LH; Chen HY; Huai C; Shang J; Mao Q; Lei CL; Luo GH; Qian J; Lu DR
World J Gastroenterol; 2016 Nov; 22(44):9813-9821. PubMed ID: 27956805
[TBL] [Abstract][Full Text] [Related]
49. Response and seroconversion rates among HBeAg-positive chronic HBV Egyptian patients treated with peginterferon alpha 2a (Pegasys), a single-centre experience.
Maklad S; Esmat G; Doss W; Abou-Zeid A; El-Din SS
Arab J Gastroenterol; 2013 Jun; 14(2):73-7. PubMed ID: 23820505
[TBL] [Abstract][Full Text] [Related]
50. Treatment of pegylated interferon-α2a in chronic hepatitis B patients demonstrating a spontaneous decline in HBV DNA after acute exacerbation.
Cai Q; Chen F; Shao X; Zhang X; Zhao Z; Gao Z
Antivir Ther; 2015; 20(2):217-24. PubMed ID: 25138110
[TBL] [Abstract][Full Text] [Related]
51. Intrahepatic response markers in chronic hepatitis B patients treated with peginterferon alpha-2a and adefovir.
Takkenberg B; Terpstra V; Zaaijer H; Weegink C; Dijkgraaf M; Jansen P; Beld M; Reesink H
J Gastroenterol Hepatol; 2011 Oct; 26(10):1527-35. PubMed ID: 21557773
[TBL] [Abstract][Full Text] [Related]
52. Difference in T helper responses during hepatitis flares in hepatitis B e antigen (HBeAg)-positive patients with genotypes B and C: implication for early HBeAg seroconversion.
Yuen MF; Wong DK; Zheng BJ; Chan CC; Yuen JC; Wong BC; Lai CL
J Viral Hepat; 2007 Apr; 14(4):269-75. PubMed ID: 17381719
[TBL] [Abstract][Full Text] [Related]
53. Extended treatment with peginterferon α-2a in combination with lamivudine or adefovir for 96 weeks yields high rates of HBeAg and HBsAg seroconversion.
Cao ZH; Ma LN; Zhang HW; Liu YL; Chen XY
J Dig Dis; 2013 Aug; 14(8):446-50. PubMed ID: 23615131
[TBL] [Abstract][Full Text] [Related]
54. Experimental HBsAg/anti-HBs complex assay for prediction of HBeAg loss in chronic hepatitis B patients treated with pegylated interferon and adefovir.
de Niet A; Jansen L; Zaaijer HL; Klause U; Takkenberg B; Janssen HL; Chu T; Petric R; Reesink HW
Antivir Ther; 2014; 19(3):259-67. PubMed ID: 24256626
[TBL] [Abstract][Full Text] [Related]
55. [The influence of hepatitis B e antigen on the expression of toll-like receptor 2 on peripheral monocytes].
Han YP; Li J; Wan YF; Kong LH; Cai J; Dong L; Liu Y; Chen N; Huang ZH
Zhonghua Gan Zang Bing Za Zhi; 2008 Oct; 16(10):739-42. PubMed ID: 18983769
[TBL] [Abstract][Full Text] [Related]
56. [Correlation of HBV genotypes to the therapeutic effect of PEG-interferon and the pathological changes of the liver of chronic hepatitis B patients].
Shen JK; Hou JL; Pang XN; Yang H; Xu ZJ
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Jul; 28(7):1217-8. PubMed ID: 18676267
[TBL] [Abstract][Full Text] [Related]
57. Efficacy of long-term interferon therapy in chronic hepatitis B patients with HBV genotype C.
Sakai T; Shiraki K; Inoue H; Okano H; Deguchi M; Sugimoto K; Ohmori S; Murata K; Nakano T
Int J Mol Med; 2002 Aug; 10(2):201-4. PubMed ID: 12119559
[TBL] [Abstract][Full Text] [Related]
58. Quantitative hepatitis B surface antigen analysis in hepatitis B e antigen-positive nucleoside-naive patients treated with entecavir.
Gish RG; Chang TT; Lai CL; de Man RA; Gadano A; Llamoso C; Tang H
Antivir Ther; 2013; 18(5):691-8. PubMed ID: 23510982
[TBL] [Abstract][Full Text] [Related]
59. Distinct evolution and predictive value of hepatitis B virus precore and basal core promoter mutations in interferon-induced hepatitis B e antigen seroconversion.
Yang HC; Chen CL; Shen YC; Peng CY; Liu CJ; Tseng TC; Su TH; Chuang WL; Yu ML; Dai CY; Liu CH; Chen PJ; Chen DS; Kao JH
Hepatology; 2013 Mar; 57(3):934-43. PubMed ID: 23112104
[TBL] [Abstract][Full Text] [Related]
60. Interferon-alpha treatment in children and young adults with chronic hepatitis B: a long-term follow-up study in Taiwan.
Hsu HY; Tsai HY; Wu TC; Chiang CL; Ni YH; Chen PJ; Chang MH
Liver Int; 2008 Nov; 28(9):1288-97. PubMed ID: 18397229
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
